Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(ombitasvir paritaprevir ritonavir dasabuvir)
392 results
  • Discontinuation of new hepatitis C drugs among Medicare patients. [Journal Article]
    Am J Manag Care. 2020 02; 26(2):84-88.Jung J, Du P, … Riley T
  • CONCLUSIONS: Real-world discontinuation of DAA therapy was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics. Efforts to increase DAA adherence would help lower patients' risk of developing resistance to future treatments and reduce potential waste of resources.
  • Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies. [Journal Article]
    J Viral Hepat. 2020 Mar; 27(3):243-260.Darvishian M, Wong S, … Janjua NZ
  • Effectiveness of direct-acting antiviral (DAA) therapies could be influenced by patient characteristics such as comorbid conditions, which could lead to premature treatment discontinuation and/or irregular medical follow-ups. Here, we evaluate loss to follow-up and treatment effectiveness of sofosbuvir/ledipasvir ± ribavirin (SOF/LDV ± RBV), ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavir…
New Search Next